Walk down the cooking oil aisle of any grocery store, and you will notice a distinct hierarchy of virtue. Extra virgin olive oil is treated like liquid gold, canola oil is marketed as the logical choice for a heart-healthy life, and palm oil is almost entirely invisible, tucked away inside the ingredient lists of processed snack foods. In food media, palm oil is routinely cast as a nutritional villain—a cheap, artery-clogging sludge that is best avoided. But if you strip away the loud geopolitical rhetoric and look strictly at the underlying biochemistry, a completely different story emerges. The relentless vilification of palm oil has far less to do with its actual impact on human health and far more to do with its unforgivable sin in the global marketplace: it is simply too inexpensive.

To truly understand palm oil, one must first look at how it compares to traditional culinary darlings like ghee or clarified butter.. For generations, clarified butter has been praised for its rich flavor and high smoke point, despite being an animal fat consisting of up to seventy-two percent saturated fat. Ghee is also heavily loaded with systemic cholesterol, containing nearly three hundred milligrams per hundred grams. Palm oil, by contrast, is a purely plant-derived lipid. It contains zero milligrams of cholesterol. More surprisingly, its saturated fat content hovers between forty-five and fifty-one percent. While it lacks the quick-burning short and medium-chain fatty acids that give ghee its rapid digestibility, palm oil cleverly compensates for this gap through its unique unsaturated structure. It balances its saturated palmitic acid with a massive volume of monounsaturated oleic acid—the exact same heart-healthy fat that dominates olive oil—and double to triple the polyunsaturated linoleic acid found in dairy fats.

When palm oil is fractionated into its liquid form, known as palm olein, it becomes an even more formidable competitor to Western seed oils. Palm olein drops its saturated fat content significantly, settling into a stable sweet spot of roughly forty percent saturated and forty-five percent monounsaturated fat. This structural blueprint gives it a profound advantage over highly unsaturated options like canola oil when exposed to intense heat. Canola oil boasts a low saturated fat profile, but its high concentration of polyunsaturated fats makes it chemically fragile. When subjected to prolonged industrial deep-frying, canola oil oxidizes rapidly, generating toxic polar compounds. Palm olein resists this degradation entirely. It behaves with the molecular stamina of an animal fat, resisting rancidity and heat damage, all while keeping its systemic cholesterol at zero. Clinical trials comparing palm olein to olive oil have shown remarkably similar outcomes regarding overall weight and metabolic markers. While palmitic acid can prompt the liver to produce more LDL cholesterol, the accompanying oleic acid concurrently stabilizes HDL cholesterol, rendering the oil’s impact on blood lipids generally neutral to mildly positive when consumed as part of a balanced diet.

Why, then, does the narrative surrounding palm oil remain so toxic? The answer lies in botanical efficiency. The oil palm is a geometric miracle of agriculture, yielding anywhere from four to ten times more oil per hectare than soy, sunflower, or canola. Because it requires a fraction of the land and labor to produce a metric ton of oil, it completely undercuts the pricing of Western-produced agricultural oils. Unable to compete on price, domestic market interests and environmental campaigns aligned, aggressively highlighting the ecological footprint of tropical deforestation. Over time, this valid environmental critique was subtly conflated with nutritional toxicity in the minds of consumers. This bias was further cemented by how palm oil arrives on Western plates. It is rarely sold as a clear, liquid bottle of cooking oil for home use; instead, it is imported as a cheap structural replacement for banned trans-fats in ultra-processed junk foods like cookies, instant noodles, and frozen pizzas. As a result, observational health studies frequently link palm oil consumption to poor cardiovascular health, failing to note that palm oil consumption is merely a proxy marker for a diet heavy in processed foods. When utilized cleanly as a domestic frying oil, palm olein is not a dietary hazard, but a stable, reliable, and perfectly healthy staple that easily holds its ground against its more expensive peers. LE

Every day, millions of South Asian households unknowingly cook with, snack on, and feed their children a substance that is part nutritional poison and part industrial heavy-metal waste. Hydrogenated Oil or Vanaspati, universally known by the brand name Dalda, is marketed as a cheap, shelf-stable alternative to desi ghee. But beneath its golden, buttery facade lies a chemical abomination that no human digestive system was ever designed to process. To call it the worst food ever produced is not alarmist rhetoric; it is a sober scientific verdict backed by decades of cardiological and toxicological research. This is not merely unhealthy food. This is edible industrial sludge, legally passed off as a cooking fat.

The creation of this ‘sludge’ begins with healthy liquid vegetable oils, such as palm or soybean oil, which are rich in unsaturated long-chain fatty acids known to support heart health. To transform these liquids into a semi-solid block that mimics the texture of ghee, manufacturers blast them with hydrogen gas at extremely high temperatures in the presence of powdered nickel catalyst. This hydrogenation process forces the oil to harden, but in doing so, it creates artificial trans fats, molecular misfits that your body does not recognize. Unlike natural fats, these trans isomers jam your metabolic machinery, raising bad LDL cholesterol while simultaneously crashing good HDL cholesterol. The World Health Organization has calculated that consuming just two grams of artificial trans fat per day, a trivial amount easily found in a single samosa fried in Dalda, increases your risk of heart disease by nearly a quarter. No other dietary component delivers such a potent cardiovascular blow at such a minuscule dose.

However, the nutritional catastrophe is only half the story. What makes Vanaspati uniquely sinister, and what separates it from other processed foods, is the toxic heavy metal that remains trapped within its fatty matrix. The nickel catalyst used to force hydrogen into the oil is never fully filtered out. Regulatory bodies like the FSSAI permit a residual nickel content of up to one part per million, but this is a legal limit, not a physiological safety threshold. Filtration is a physical process, and straining microscopic metal dust out of a thick, greasy block is commercially impossible. In practice, particularly in unregulated small-scale mills, the residual nickel can climb far higher. When you eat Vanaspati, you are not just ingesting damaged fats; you are ingesting a known carcinogenic heavy metal that slowly leaches into your body over hours of digestion. The acidic environment of the stomach releases ionic nickel from these trapped particles, generating massive oxidative stress that directly damages DNA and inhibits the body’s natural repair mechanisms.

The consequences of this chronic metal exposure are terrifyingly broad. The International Agency for Research on Cancer classifies nickel compounds as Group 1 carcinogens, with chronic oral intake specifically linked to gastrointestinal and colorectal cancers. But cancer is merely the endpoint of a long cascade of damage. Nickel bioaccumulates in human tissue, with a biological half-life of up to four decades. It primarily deposits in the kidneys, where it induces proximal tubular necrosis, and in the liver, leading to interstitial fibrosis over time. Dermatologists across the subcontinent frequently see patients with unexplained hand and foot eczema, a manifestation of systemic nickel allergy syndrome exacerbated by dietary intake. Respiratory irritation, chronic organ scarring, and mitochondrial dysfunction are all well-documented outcomes of low-level, long-term nickel exposure. The tragedy is that this metal residue is entirely avoidable, yet it remains a silent, invisible contaminant in millions of daily meals.

What makes this situation even more insidious is the synergistic destruction caused by the combination of trans fats and heavy metals. The artificial trans fats compromise the integrity of your cell membranes, making them more permeable and less selective. Through these weakened barriers, nickel ions slip directly into the mitochondria, the power plants of your cells. Once inside, nickel displaces essential minerals like magnesium and zinc from enzymatic sites, crippling energy production and triggering ferroptosis, a highly inflammatory form of cell death. This is not a theoretical risk; it is a daily, ongoing biological assault occurring in the bodies of millions.

Perhaps most frustrating is the regulatory charade. Food inspectors in India and Pakistan routinely test for trans-fat content but rarely, if ever, test for heavy metal residues in the final retail product, as such analysis using atomic absorption spectroscopy is expensive and time-consuming. We have created a food that is simultaneously atherogenic, carcinogenic, and hepatotoxic. It damages the heart, poisons the liver, scars the kidneys, and mutates the DNA—all in one inexpensive, widely available package. The only sane response is to treat Dalda or Vanaspati not as food, but as industrial waste.

For decades, the weighing scale has been treated almost like a health report card. Lose a few kilograms and we congratulate ourselves; gain a few and we worry. Body weight and Body Mass Index (BMI) have become familiar shorthand for judging whether someone is healthy. But a growing understanding of ageing and metabolism suggests that the scale may be telling us only half the story. The more meaningful measure of health may be not how much we weigh, but how much of that weight is muscle.

Two people can weigh exactly the same and have completely different bodies. One may have substantial muscle, relatively little visceral fat and good physical strength; the other may have less muscle and considerably more fat. Their weighing scales will show the same number, but their metabolic health, physical capacity and prospects for independent living may be very different.

Muscle is far more than the tissue that allows us to lift weights or look athletic. It is one of the body’s most important metabolic organs. After a meal, skeletal muscle accounts for the bulk of insulin-stimulated glucose disposal—often estimated at roughly 70 to 80 per cent under insulin-stimulated conditions. In simple terms, muscles act as a huge glucose sink, taking glucose out of the bloodstream to use as energy or store as glycogen. This makes healthy muscle particularly important for maintaining good glucose regulation.

Muscle is also metabolically active at rest and consumes more energy than an equivalent amount of fat. The difference should not be exaggerated: a kilogram of muscle does not burn hundreds of calories simply by sitting inside the body. But the larger metabolic importance of muscle lies in its ability to store and use glucose, support physical activity and maintain the body’s capacity to respond to nutritional and metabolic demands.

Then comes ageing. Muscle mass generally reaches its peak in early adulthood, often during the 20s and early 30s. The muscle built during those years can be thought of as a physiological reserve. The larger the reserve built before age-related decline begins, the more capacity there may be to withstand the gradual losses that accompany ageing. In that sense, building muscle in youth is rather like building up savings for retirement: the benefit may become most apparent decades later.

This does not mean, however, that the story is decided at 30. Far from it. Muscle remains remarkably responsive to resistance training throughout life. Older adults can strengthen their muscles and improve physical function even when they begin exercising relatively late. The gains may be slower than in youth, but the body’s capacity to adapt does not suddenly disappear with age.

This matters because maintaining the same body weight becomes increasingly difficult as we grow older. As muscle declines, resting energy expenditure tends to fall. Physical activity may decline as well. If food intake remains unchanged, the resulting energy surplus can gradually become body fat. The most deceptive part is that the weighing scale may barely move. A person can remain at approximately the same weight while losing muscle and gaining fat. The number has stayed constant, but the body composition has changed dramatically.

The consequences extend beyond appearance. Muscle increasingly becomes a determinant of independence in later life. Low muscle mass, particularly when accompanied by reduced muscle strength, is associated with poorer mobility and a greater risk of falls. Everyday actions that younger people take for granted—rising from a chair, climbing stairs, carrying groceries, getting out of a car or walking confidently across a street—depend upon adequate muscular strength.

That is why the real objective of healthy ageing should not simply be to remain thin or maintain an arbitrary number on the weighing scale. It should be to preserve muscle, strength and physical function. Sarcopenia—the age-related decline in muscle mass, strength and function—is not merely an aesthetic problem. It can gradually erode the physical independence that gives older life its dignity.

The good news is that muscle is an unusually forgiving investment. The 20s and 30s may be the best years to build a substantial reserve, but the 40s, 50s, 60s, 70s and beyond are not too late. Resistance exercise, adequate protein, good nutrition and regular physical activity can help preserve or rebuild muscle.

Perhaps, therefore, we should stop asking only, “What do you weigh?” A better question might be, “How strong are you, and how much muscle are you carrying?” The weighing scale measures kilograms. Muscle measures capability. And as life expectancy increases, capability—not merely body weight—may prove to be the more valuable currency of healthy ageing.

In the quiet world inside our intestines lives a vast community of microorganisms that do far more than digest food. They shape immunity, metabolism, mood, and—most strikingly—the health of our hearts. What was once dismissed as digestive trivia has emerged as a central player in coronary artery disease, the leading killer worldwide. The evidence is no longer fringe; it is mechanistic, reproducible, and increasingly actionable.

The gut-heart axis operates largely through metabolites. Certain bacteria convert dietary choline and carnitine—abundant in red meat and egg yolks—into trimethylamine, which the liver oxidizes into trimethylamine N-oxide, or TMAO. Elevated TMAO drives foam-cell formation, impairs cholesterol transport, heightens platelet reactivity, and fuels vascular inflammation. At the same time, beneficial microbes ferment fiber into short-chain fatty acids such as butyrate and propionate. These molecules lower blood pressure, calm systemic inflammation, strengthen the intestinal barrier, and protect the endothelium. When the balance tips toward dysbiosis, protective species dwindle, pro-inflammatory pathways surge, and the arteries pay the price.

A 2025 metagenomic study crystallized these links. Comparing patients with coronary artery disease to matched healthy controls, researchers identified fifteen bacterial species whose abundances differed significantly. Members of the Lachnospiraceae family, some associated with TMAO production, were enriched in disease. In contrast, short-chain fatty acid producers, notably Faecalibacterium prausnitzii and Slackia isoflavoniconvertens, were depleted. Pathway analysis revealed overactivation of the urea cycle and L-citrulline biosynthesis, alongside reduced capacity for beneficial fermentation. Even more telling were the strain-level differences: the same species, including Akkermansia muciniphila and Faecalibacterium prausnitzii, carried distinct genetic toolkits depending on whether they inhabited a diseased or healthy gut. One protective strain of F. prausnitzii harbored a gene that avoids producing trimethylamine, underscoring that function, not mere presence, determines risk.

These discoveries have moved the field beyond description into intervention. Scientists are testing a spectrum of gut-directed strategies. The most accessible remains diet. Mediterranean and high-fiber patterns reliably boost short-chain fatty acid producers, while limiting TMAO precursors, delivering measurable improvements in lipid profiles and inflammatory markers. Probiotics and prebiotics offer more targeted leverage. Specific strains of Lactobacillus, Bifidobacterium, and Akkermansia have shown, in smaller trials, reductions in TMAO, modest cholesterol lowering, better endothelial function, and decreased inflammation. Synbiotics that combine both approaches are under active study.

Pharmacological precision is also advancing. Mechanism-based inhibitors of microbial TMA lyases—compounds such as dimethylbutanol and its more potent analogs—block the first step of TMAO generation inside the gut without killing the microbes themselves. In animal models they shrink plaques, dampen thrombosis, and lower circulating TMAO with minimal systemic exposure. Engineered probiotics coated with responsive nanoparticles take the concept further, delivering sustained local inhibition while scavenging oxidative stress. Fecal microbiota transplantation, though still limited by safety and standardization concerns for coronary disease, has demonstrated proof-of-principle benefits in metabolic syndrome and is being refined into more controlled live biotherapeutics.

None of these approaches is ready to replace statins, blood-pressure control, or smoking cessation. Most human data still rest on surrogate endpoints rather than hard clinical events. Large, adequately powered trials are essential, and individual microbiome variability demands precision rather than one-size-fits-all prescriptions. Yet the trajectory is clear. We are moving from treating the downstream consequences of atherosclerosis to interrupting upstream microbial drivers.

The implication is profound. Coronary artery disease is not solely a disease of cholesterol and blood pressure; it is also a disease of microbial ecology. Supporting a diverse, fiber-nourished gut community is no longer optional wellness advice—it is cardiovascular prevention. As research accelerates from mapping species to engineering therapies, the next decade may bring microbiome diagnostics that flag risk before plaques form and interventions that restore protective functions with the same rigor we apply to lipid-lowering drugs. The heart, it turns out, listens closely to the gut. It is time medicine did the same. OK